Key Points
- Teva CEO Richard Francis sold 250,000 shares for $10.56 million, reducing his direct stake by 21.23% to 927,529 shares.
- Teva beat quarterly earnings and revenue expectations, reporting EPS of $0.86 versus $0.72 forecast and revenue of $4.39 billion versus $4.23 billion; revenue declined 1.9% year over year.
- Analyst sentiment was broadly positive: 13 analysts rated the stock Buy, and the consensus rating was Moderate Buy with an average price target of $48.15.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) CEO Richard Francis sold 250,000 shares of the business's stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total value of $10,560,000.00. Following the sale, the chief executive officer directly owned 927,529 shares of the company's stock, valued at $39,178,824.96. This represents a 21.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Teva Pharmaceutical Industries Stock Performance
Shares of Teva Pharmaceutical Industries stock opened at $43.52 on Friday. The company has a market cap of $50.72 billion, a PE ratio of 101.22, a price-to-earnings-growth ratio of 4.05 and a beta of 0.97. Teva Pharmaceutical Industries Ltd. has a 52 week low of $24.01 and a 52 week high of $44.31. The business has a 50 day moving average price of $40.00 and a 200-day moving average price of $35.01. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.14. The company had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company's revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the company earned $0.78 earnings per share. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.
Analyst Ratings Changes
TEVA has been the topic of a number of analyst reports. TD Cowen lifted their price objective on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a "buy" rating in a report on Wednesday, November 4th. HC Wainwright initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, November 2nd. They issued a "buy" rating and a $52.00 target price for the company. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an "overweight" rating in a report on Thursday. Oppenheimer raised their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an "outperform" rating in a research report on Friday, October 9th. Finally, Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c+)" rating in a report on Wednesday, November 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $48.15.
Get Our Latest Stock Report on Teva Pharmaceutical Industries
Top Teva Pharmaceutical Industries Stories
Investors following TEVA have been watching these stories:
- Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and reiterated an Overweight rating, signaling confidence in further upside. Piper Sandler analyst ratings
- Neutral Sentiment: Healthcare stocks broadly declined Wednesday afternoon, a sector headwind that may have affected trading but does not reflect Teva-specific fundamentals. Healthcare sector update
- Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.6 million, reducing his stake by 21.23%. EVP Richard Daniell also sold 20,003 shares and 25,000 shares in separate transactions. These sizable insider sales may raise concerns about executive confidence, although the filings do not state the reasons for the transactions. CEO SEC filing EVP SEC filing
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Several large investors have recently made changes to their positions in the business. Root Financial Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $33,000. Cornerstone Planning Group LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock worth $27,000 after buying an additional 755 shares during the last quarter. Western Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $43,000. Sunbelt Securities Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $45,000. Finally, CX Institutional bought a new position in Teva Pharmaceutical Industries during the second quarter valued at about $54,000. 54.05% of the stock is owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Company Profile
(
Get Free Report)
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
